Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases.

Alhalabi, Omar; Soomro, Zaid; Sun, Ryan; Hasanov, Elshad; Albittar, Aya; Tripathy, Debu; Valero, Vicente; Ibrahim, Nuhad K

Alhalabi, Omar; Soomro, Zaid; Sun, Ryan; Hasanov, Elshad; Albittar, Aya; Tripathy, Debu; Valero, Vicente; Ibrahim, Nuhad K.

Afiliação

Alhalabi O; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. oalhalabi@mdanderson.org.
Soomro Z; Departments of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sun R; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hasanov E; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Albittar A; Investigational Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tripathy D; Department of Medicine, the State University of New York Upstate Medical University, Syracuse, NY, USA.
Valero V; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ibrahim NK; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

NPJ Breast Cancer ; 7(1): 28, 2021 Mar 19.

Article em En | MEDLINE | ID: mdl-33742001

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: NPJ Breast Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google